Home / Products / Pharma / General / By Brand Name / Sinalax
|NAME||STRENGTH||PACK SIZE||DOSAGE FORM|
Sinalax is a disaccharide derivatives consisting of galactose and sorbitol, which is only minimally absorbed and is not hydrolysed by the disaccharidases of the GIT and thus reaches the colon unchanged. In the colon it is broken down to short chain low molecular weight organic acids by the intestinal flora, resulting in an increase in osmotic pressure in the colon, thereby causing an increase in the stool water content and stool volume, which explains the laxative effect. Lactitol produces its effect in the lumen of the colon, where it is virtually 100% bioavailable. It is absorbed only in minimal amounts. Up to 2% can be found unchanged in the urine.
Indications And Uses
• Constipation • Acute and chronic portal systemic encephalopathy.
Dosage And Administration
Sinalax can be mixed with hot or cold beverages, puddings etc. Dosage will require adjustment to obtaine one daily bowel movement in constipated patients and two daily bowel movements in patients with portal systemic encephalopathy.
At the start of the treatment with lactitol may produce abdominal discomforts such as flatulence, pain, cramps or sensation of fullness. Such effects tend to diminish or disappear after a few days of regular intake of Lactitol. Occasionally, nausea or anal pruritus has been reported in some cases.
• Elderly or debilitated patients receiving long-term treatment with lactitol should have their serum electrolytes monitored regularly. • As for all laxatives, pre-existing fluid or electrolyte imbalance should be corrected before starting treatment with lactitol. • Following treatment of Lactitol, hydrogen may accumulate in the bowel. Patients who need to undergo electrocauterisation procedure should therefore have a thorough bowel cleansing with a non-fermentable solution. • Lactitol is not recommended in case s of ileostomy or colostomy. • Prolonged use of laxatives without interruption should be avoided.
Antacids and neomycin should not be given simultaneously with Lactitol to cirrhotic patients with portal systemic encephalopathy. Lactitol may increase potassium loss caused by other drugs e.g. thiazide diuretics, corticosteroids, carbenoxolone, amphotericin B and it may enhance the risk of toxic effects of glycosides in patients receiving concomitant therapy.
Each box contains 10 sachets of Lactitol Monohydrate. Each sachet contains 10 gm of Lactitol Monohydrate.